AnGes MG, Inc. (4563) - Financial and Strategic SWOT Analysis Review

Date: July 5, 2016
Pages: 44
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5BCD768AC2EN
Leaflet:

Download PDF Leaflet

AnGes MG, Inc. (4563) - Financial and Strategic SWOT Analysis Review
AnGes MG, Inc. (4563) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

AnGes MG, Inc. (AnGes) is a biopharmaceutical company which discovers and develops gene and nucleotide based drugs and reagents for use in functional analysis of genetic medication. The company specializes in R&D and practical application of genetic medicine. It develops of two new medicines, namely, Collategene, a hepatocyte growth factor (HGF) genetic medicine that regenerates blood vessels improving blood circulation and NF-KB decoy oligonuvleotide for the treatment of atopic dermatitis. The company is also into the development of medical devices, NF-KB decoy oligo coated PTA Balloon catheter for the prevention of vascular restenosis; and functional peptide, Curepeptin for wound care management. It has collaborations with pharmaceutical companies such as Tella, Daiichi Sankyo, Nippon Zoki, Mitsubishi Tanabe, Shionogi and others for the development and commercialization of its products. AnGes is headquartered in Osaka, Japan

AnGes MG, Inc. Key Recent Developments

Jun 15, 2015: Increase in Titers of Antibodies against Ebola Glycoprotein Confirmed in Initial Equine Study for Ebola Polyclonal Antibody Therapy Using DNA Vaccine Technology
Jan 14, 2015: AnGes to Develop Equine Polyclonal Antibody Therapy for Ebola Virus Using DNA Vaccine Technology in Japan

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

AnGes MG, Inc. - Key Facts
AnGes MG, Inc. - Key Employees
AnGes MG, Inc. - Key Employee Biographies
AnGes MG, Inc. - Major Products and Services
AnGes MG, Inc. - Pharmaceutical Pipeline Products Data
AnGes MG, Inc., Pipeline Products by Therapy Area
AnGes MG, Inc., Pipeline Products by Development Phase
AnGes MG, Inc. - History
AnGes MG, Inc. - Company Statement
AnGes MG, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

AnGes MG, Inc. - Business Description
AnGes MG, Inc. - Corporate Strategy
AnGes MG, Inc. - SWOT Analysis
SWOT Analysis - Overview
AnGes MG, Inc. - Strengths
Strength - Focused R&D Activities
Strength - Strategic Alliances
Strength - Patent Portfolio
AnGes MG, Inc. - Weaknesses
Weakness - High Operating Expenses
Weakness - Product Discontinuation
AnGes MG, Inc. - Opportunities
Opportunity - Market Potential - Ischemic Stroke Therapeutics
Opportunity - New Partnerships
Opportunity - Demographic Trends
AnGes MG, Inc. - Threats
Threat - Competition and Technological Change
Threat - Government Regulations
Threat - Uncertain R&D Outcomes
AnGes MG, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

AnGes MG, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
AnGes MG, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
AnGes MG, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 15, 2015: Increase in Titers of Antibodies against Ebola Glycoprotein Confirmed in Initial Equine Study for Ebola Polyclonal Antibody Therapy Using DNA Vaccine Technology
Jan 14, 2015: AnGes to Develop Equine Polyclonal Antibody Therapy for Ebola Virus Using DNA Vaccine Technology in Japan

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

AnGes MG, Inc., Key Facts
AnGes MG, Inc., Key Employees
AnGes MG, Inc., Key Employee Biographies
AnGes MG, Inc., Major Products and Services
AnGes MG, Inc., Number of Pipeline Products by Therapy Area
AnGes MG, Inc., Number of Pipeline Products by Development Stage
AnGes MG, Inc., Pipeline Products By Therapy Area and Development Phase
AnGes MG, Inc., History
AnGes MG, Inc., Other Locations
AnGes MG, Inc., Subsidiaries
AnGes MG, Inc., Key Competitors
AnGes MG, Inc., Ratios based on current share price
AnGes MG, Inc., Annual Ratios
AnGes MG, Inc., Interim Ratios
AnGes MG, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
AnGes MG, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
AnGes MG, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

AnGes MG, Inc., Pipeline Products by Therapy Area
AnGes MG, Inc., Pipeline Products by Development Phase
AnGes MG, Inc., Performance Chart (2011 - 2015)
AnGes MG, Inc., Ratio Charts
AnGes MG, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
AnGes MG, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

AnGes MG, Inc. (4563) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: